Takeda Presents P-III (LATITUDE) Studies Data on Zasocitinib in Plaque Psoriasis at AAD 2026

Shots:

• The 2 P-III (Latitude PsO 3001 & PsO 3002) trials assessed zasocitinib in 693 & 1108 adults with mod. to sev. PsO, with plans for NDA submission to FDA & other authorities starting Takeda’s FY’26    
• PsO 3001 showed 71.4% achieved sPGA 0/1 vs PBO (10.7%) & apremilast (32.1%), with 39.9% reaching sPGA 0 (vs 0.7% & 8%), plus 61.3% & 33.4% pts achieved PASI 90 (vs 5% & 16.8%) & PASI 100 (vs 0.7% & 2.9%), respectively at 16wks. Responses continued to improve through Wk. 24 in both studies
• PsO 3002 showed 69.2% achieved sPGA 0/1 vs PBO (12.6%) & apremilast (29.7%), with sPGA 0 in 33.7% (vs 1.4% & 6.5%), plus 51.9% & 25.2% pts reached PASI 90 (vs 4% & 15.9%) & PASI 100 (vs 1.1% & 4.3%), respectively. Rapid Wk. 4 response (PASI 75: 16.8% vs 4.3% for PBO), & >90% durability at Wk. 60 was also seen

Ref: Takeda  |   Image: Takeda   |   Press Release

Related News: Takeda and Protagonist Therapeutics Report the US FDA’s NDA Acceptance with Priority Review of Rusfertide to Treat Polycythemia Vera

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com